187 related articles for article (PubMed ID: 30410083)
21. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Martín A; Caballero MD; Pérez-Simón JA; López-Holgado N; Mateos MV; Cañizo MC; Miguel JF
Bone Marrow Transplant; 2004 Oct; 34(8):675-82. PubMed ID: 15334049
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Philippe L; Helias P; Puyraveau M; Boulahdour H; Deconinck E; Daguindau E
Bone Marrow Transplant; 2016 Aug; 51(8):1140-2. PubMed ID: 27042844
[No Abstract] [Full Text] [Related]
23. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
Kothari J; Foley M; Peggs KS; Mackenzie S; Thomson K; Morris E; Ardeshna KM; Virchis AE; Linch DC; Lambert J
Bone Marrow Transplant; 2016 Oct; 51(10):1397-1399. PubMed ID: 27214072
[No Abstract] [Full Text] [Related]
24. Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
Damaj G; Cornillon J; Bouabdallah K; Gressin R; Vigouroux S; Gastinne T; Ranchon F; Ghésquières H; Salles G; Yakoub-Agha I; Gyan E
Bone Marrow Transplant; 2017 Jul; 52(7):941-949. PubMed ID: 28112752
[TBL] [Abstract][Full Text] [Related]
25. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
[TBL] [Abstract][Full Text] [Related]
26. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
27. Effective chemomobilization with etoposide and cytarabine (EC regimen) in lymphoma patients: a single-center, retrospective, observational study.
Koyama D; Nishiwaki S; Harada Y; Yamamoto S; Kurahashi S; Sugimoto T; Iwasaki T; Sugiura I
Jpn J Clin Oncol; 2017 Sep; 47(9):820-825. PubMed ID: 28541555
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Berglund A; Enblad G; Carlson K; Glimelius B; Hagberg H
Eur J Haematol; 2000 Jul; 65(1):17-22. PubMed ID: 10914935
[TBL] [Abstract][Full Text] [Related]
29. Sodium and potassium excretion changes and bone marrow recovery after chemotherapy.
Kiss I; Tomasek J
Stem Cells; 1999; 17(4):233-4. PubMed ID: 10437987
[No Abstract] [Full Text] [Related]
30. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD
Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
[TBL] [Abstract][Full Text] [Related]
31. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
[TBL] [Abstract][Full Text] [Related]
32. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
[TBL] [Abstract][Full Text] [Related]
33. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Visani G; Malerba L; Stefani PM; Capria S; Galieni P; Gaudio F; Specchia G; Meloni G; Gherlinzoni F; Giardini C; Falcioni S; Cuberli F; Gobbi M; Sarina B; Santoro A; Ferrara F; Rocchi M; Ocio EM; Caballero MD; Isidori A
Blood; 2011 Sep; 118(12):3419-25. PubMed ID: 21816830
[TBL] [Abstract][Full Text] [Related]
34. [Autologous transplant with BEAM protocol in lymphoma].
Caballero D; Rubio V; Rifon J; Heras I; García-Sanz R; Vidriales B; Pérez-Simón JA; del Cañizo C; González M; León A; Jean-Paul E; Rocha E; Vicente V; San Miguel JF
Sangre (Barc); 1997 Apr; 42 Suppl 1():46-9. PubMed ID: 9381303
[No Abstract] [Full Text] [Related]
35. BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Ron-Magaña AL; Fernandez-Vargas OE; Barrera-Chairez E; Ron-Guerrero CS; Bañuelos-Ávila AJ
Ann Transplant; 2019 Oct; 24():584-587. PubMed ID: 31636248
[TBL] [Abstract][Full Text] [Related]
36. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
37. LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
Khattry N; Gupta A; Jain R; Gore A; Thippeswamy R; Jeevangi N; Kannan S; Nair R; Saikia T
Int J Hematol; 2016 Mar; 103(3):292-8. PubMed ID: 26729297
[TBL] [Abstract][Full Text] [Related]
38. High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.
Hyun SY; Cheong JW; Kim SJ; Min YH; Yang DH; Ahn JS; Lee WS; Ryoo HM; Do YR; Lee HS; Lee JH; Oh SY; Suh C; Yhim HY; Kim JS
Biol Blood Marrow Transplant; 2014 Jan; 20(1):73-9. PubMed ID: 24141009
[TBL] [Abstract][Full Text] [Related]
39. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.
Singer S; Sharma N; Dean R; Zhao Q; Abounader D; Elder P; Hofmeister CC; Benson DM; Rosko A; Penza S; Andritsos L; Vasu S; Jaglowski S; William BM; Bolwell B; Pohlman B; Kalaycio M; Jagadeesh D; Hill B; Sobecks R; Devine SM; Majhail NS; Efebera YA
Bone Marrow Transplant; 2019 Oct; 54(10):1553-1561. PubMed ID: 30718797
[TBL] [Abstract][Full Text] [Related]
40. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
